Breast Cancer Research and Treatment

, Volume 144, Issue 3, pp 591–597 | Cite as

Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103

  • Kathryn J. RuddyEmail author
  • Anne O’Neill
  • Kathy D. Miller
  • Bryan P. Schneider
  • Emily Baker
  • Joseph A. Sparano
  • Chau Dang
  • Donald W. Northfelt
  • George W. SledgeJr.
  • Ann H. Partridge
Clinical trial


This study aimed to investigate whether pre-chemotherapy anti-mullerian hormone (AMH) is a biomarker for chemotherapy-related amenorrhea (CRA) in breast cancer patients. A multicenter randomized controlled trial, ECOG5103, assigned patients with early stage breast cancer to standard doxorubicin-cyclophosphamide followed by paclitaxel with either placebo or one of two durations of bevacizumab therapy. Five hundred ninety-one patients were part of the decision-making/quality of life substudy, in which there were surveys from baseline through 18-month follow-up. One hundred twenty-four women were included in this analysis of menses data because they were premenopausal at enrollment, responded to the 12-month survey, had not undergone bilateral oophorectomy or ovarian function suppression before that survey, and had serum banked for research before chemotherapy. One hundred of the 124 also responded to the 18-month survey. Median age was 45 years (range 25–55), and median serum AMH level was 0.11 ng/mL (range 0.01–8.63) prior to treatment. Eighty-two percent had CRA at 12 months, and 81 % at 18 months. In multivariate analyses, older age (p = 0.0003) was the only statistically significant predictor of 12-month CRA, but at 18-months, lower pre-chemotherapy AMH (p = 0.04) and older age (p = 0.008) were both statistically significant predictors of CRA. Race, bevacizumab therapy, and tamoxifen use were not statistically significantly associated with CRA after adjustment for AMH and age. Pre-chemotherapy AMH level is a potential novel biomarker for CRA in premenopausal women with early stage breast cancer. Further research to evaluate the clinical utility of AMH testing is warranted.


Breast neoplasms Fertility Biomarkers Chemotherapy Adjuvant 



This study was supported by Public Health Service Grants CA23318, CA66636, CA21115, CA49883, CA14958, CA77651, CA25224, CA32291, as well as a Komen Promise Grant (PI: Schneider) and funds from the Breast Cancer Research Foundation. Chau Dang receives research funding from Roche/Genentech and GlaxoSmithKline and also serves as a consultant/advisor for Pfizer. Kathy Miller, Bryan Schneider, and Joseph Sparano have consultant/advisory roles Genentech, and Dr. Schneider is on the Genentech Speaker’s Bureau. George Sledge receives remuneration from Genentech.


  1. 1.
    Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, Naftalis E, Naughton MJ (2010) Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 116(13):3102–3111. doi: 10.1002/cncr.25106 PubMedCrossRefGoogle Scholar
  2. 2.
    Zec I, Tislaric-Medenjak D, Megla ZB, Kucak I (2011) Anti-Mullerian hormone: a unique biochemical marker of gonadal development and fertility in humans. Biochem Med (Zagreb) 21(3):219–230CrossRefGoogle Scholar
  3. 3.
    Seifer DB, Baker VL, Leader B (2011) Age-specific serum anti-Mullerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril 95(2):747–750. doi: 10.1016/j.fertnstert.2010.10.011 PubMedCrossRefGoogle Scholar
  4. 4.
    Celik E, Bastu E, Dural O, Yasa C, Buyru F (2013) Relevance of anti-Mullerian hormone on in vitro fertilization outcome. Clin Exp Obstet Gynecol 40(1):66–69PubMedGoogle Scholar
  5. 5.
    Wunder DM, Guibourdenche J, Birkhauser MH, Bersinger NA (2008) Anti-Mullerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 90(6):2203–2210. doi: 10.1016/j.fertnstert.2007.10.078 PubMedCrossRefGoogle Scholar
  6. 6.
    La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P, Volpe A (2004) Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 19(12):2738–2741. doi: 10.1093/humrep/deh508 PubMedCrossRefGoogle Scholar
  7. 7.
    Lutchman Singh K, Muttukrishna S, Stein RC, McGarrigle HH, Patel A, Parikh B, Groome NP, Davies MC, Chatterjee R (2007) Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 96(12):1808–1816. doi: 10.1038/sj.bjc.6603814 PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21(10):2583–2592. doi: 10.1093/humrep/del201 PubMedCrossRefGoogle Scholar
  9. 9.
    Anderson RA, Cameron DA (2011) Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 96(5):1336–1343. doi: 10.1210/jc.2010-2582 PubMedCrossRefGoogle Scholar
  10. 10.
    Anderson RA, Rosendahl M, Kelsey TW, Cameron DA (2013) Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer. doi: 10.1016/j.ejca.2013.07.014 PubMedCentralGoogle Scholar
  11. 11.
    Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, Lyons P, Behera M, Copland S, Kimmick G, Shaw H, Snyder S, Antenos M, Woodruff T, Blackwell K (2008) A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 26(3):286–295. doi: 10.1080/07357900701829777 PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Henry NL, Xia R, Schott AF, McConnell D, Banerjee M, Hayes DF (2014) Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist 19(1):68–74. doi: 10.1634/theoncologist.2013-0145 PubMedCrossRefGoogle Scholar
  13. 13.
    Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, Ginsburg E (2010) Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 94(2):638–644. doi: 10.1016/j.fertnstert.2009.03.045 PubMedCrossRefGoogle Scholar
  14. 14.
    Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362(22):2053–2065. doi: 10.1056/NEJMoa0909638 PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Moore HC (2000) Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer. Curr Oncol Rep 2(6):587–593PubMedCrossRefGoogle Scholar
  16. 16.
    Duffy LS, Greenberg DB, Younger J, Ferraro MG (1999) Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. Psychosomatics 40(4):304–308. doi: 10.1016/S0033-3182(99)71223-5 PubMedCrossRefGoogle Scholar
  17. 17.
    Henry NL, Xia R, Banerjee M, Gersch C, McConnell D, Giacherio D, Schott AF, Pearlman M, Stearns V, Partridge AH, Hayes DF (2013) Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol 24(8):2011–2016. doi: 10.1093/annonc/mdt149 PubMedCrossRefGoogle Scholar
  18. 18.
    Meng K, Tian W, Zhou M, Chen H, Deng Y (2013) Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels. World J Surg Oncol 11:101. doi: 10.1186/1477-7819-11-101 PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Zhou WB, Yin H, Liu XA, Zha XM, Chen L, Dai JC, Tao AD, Ma JJ, Ling LJ, Wang S (2010) Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. BMC Cancer 10:281. doi: 10.1186/1471-2407-10-281 PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Wolmark N, Ganz PA (2009) Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 113(2):315–320. doi: 10.1007/s10549-008-9937-0 PubMedCrossRefGoogle Scholar
  21. 21.
    Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, Lee H, Lee ES, Kang HS, Kim SW (2009) Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 115(2):335–342. doi: 10.1007/s10549-008-0071-9 PubMedCrossRefGoogle Scholar
  22. 22.
    Newman H, Finger PT, Chin KJ, Pavlick AC (2011) Systemic bevacizumab (Avastin) for exudative retinal detachment secondary to choroidal melanoma. Eur J Ophthalmol 21(6):796–801. doi: 10.5301/EJO 2011.6477PubMedCrossRefGoogle Scholar
  23. 23.
    Joshi DD, Banerjee T (2008) Vascular endothelial growth factor (VEGF) receptor antibody bevacizumab (avastin) induces regression of renal cell carcinoma in an adolescent resulting in residual tumorectomy. Pediatr Blood Cancer 50(4):903–904. doi: 10.1002/pbc.21243 PubMedCrossRefGoogle Scholar
  24. 24.
  25. 25.
    Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH (2010) The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116(4):791–798. doi: 10.1002/cncr.24835 PubMedCrossRefGoogle Scholar
  26. 26.
    Armed Forces Health Surveillance Center (2013) Female infertility, active component service women, U.S. Armed Forces, 2000–2012. MSMR 20(9):8–12.

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Kathryn J. Ruddy
    • 1
    Email author
  • Anne O’Neill
    • 2
  • Kathy D. Miller
    • 3
  • Bryan P. Schneider
    • 3
  • Emily Baker
    • 2
  • Joseph A. Sparano
    • 4
  • Chau Dang
    • 5
  • Donald W. Northfelt
    • 6
  • George W. SledgeJr.
    • 7
  • Ann H. Partridge
    • 2
  1. 1.Mayo ClinicRochesterUSA
  2. 2.Dana-Farber Cancer InstituteBostonUSA
  3. 3.Indiana University Melvin and Bren Simon Cancer CenterIndianapolisUSA
  4. 4.Montefiore Hospital and Medical CenterBronxUSA
  5. 5.Memorial Sloan Kettering Cancer CenterNew YorkUSA
  6. 6.Mayo ClinicScottsdaleUSA
  7. 7.Stanford UniversityPalo AltoUSA

Personalised recommendations